

Review

## Excel Diet for Homocystinuria: How Can We Use?

Binnur TÜZÜN, MD

Address: Özel Çapa Hastanesi, Necip Asım sokak, 23 Çapa-Istanbul-Turkey

E-mail: dena\_mik@yahoo.com

Corresponding Author: Binnur Tüzün, MD, Özel Çapa Hastanesi, Necip Asım sokak, 23 Çapa-Istanbul-Turkey

Published:

J Turk Acad Dermatol 2010; **4** (1): 04102r

This article is available from: <http://www.jotad.org/2009/4/jotad04102r.pdf>

**Key Words:** methionine, cysteine, homocystein, diet

### Abstract

**Background:** Methionine restricted diet prevents homocystinuria complications, seems like *Marfan* syndrome. Homocystinuria is a metabolism disease but *Marfan* syndrome is a genetic disorder have similar symptoms. But only homocystinuria have neuropsychologic abnormalities and high methionine levels. Homocystein is an intermediate oxidized product, transform both of methionine or cystein. High methionine levels lead to neuropsychologic features, may be also premature ageing, in marfanoid persons with homocystinuria, because of creates over-methylating status in whole organism and also DNA. These high methylating status have found in cancer patients.

### Introduction

Diet plays an important role on the body molecular composition. Gout, diabetes, hypertension, coeliac and phenylketonuria are known as the diseases that needs a strongly and traditional diet control. Purine control; sugar control; salt control; gluten-free diet and phenylalanin free diet are recommended for above diseases, respectively.

The clues from the patients have these diseases, leads to dermatologists to search the pathways of skin diseases and modern approaches to excel diet modifying, from DNA nucleotide sequence and aminoacids to protein synthesis, enzyme and catalysts belongs dermatologic diseases. For example DNA nucleotide methylation differs DNA melting point and autofluorescence of extracted DNA from cancer patients [1]. The clues from ho-

mocystinuria support cancer, diabetes, aging research as a methylating status [2].

### Marfan Syndrome and Marfanoid Persons with Homocystinuria

Marfan syndrome is an autosomal dominant, elastic fibril disease have an unique phenotyping feature. Marfanoid patients have a dolichocephale and thin body structure and accompying defects pectus excavatus or pectus carinatus, scoliosis, arachnodactyly [3], joint hypermobility, muscle contractions [4, 5], aorta and hearth diseases, ocular finding as lens subluxation [5, 6], intracranial hypertension, respiratory function disorders because of fibrillin-1 genetic defect [7, 8, 9, 10, 11]. Homozygotic persons have several features of the syndrome, besides heterozygotic persons have only few features [12]. The most of the marfanoid persons shows homocystinuria or homocystinuria with

methylmalonic aciduria and needs excellent diet modifications [7, 9, 13, 14].

### Biochemistry of Homocystein Metabolism

Blood homocystein and methionine levels are increased and cysteine level is decreased in homocystinuria generally. Homocystin, composed of two homocystein molecules by the way of reduction, is an oxidized intermediate product. The source of homocystein is generally methionine. Homocystein transforms to cysteine or methionine by the two-way. Whether homocystein and serine are composed of cysteine, or partly is also shows remethylation of homocystein to methionine by the catalysis of B<sub>12</sub> (cyanocobalamin) and folate in healthy persons [15, 16, 17]. But the patients with homocystinuria blood homocysteine levels are found high as an intermediate oxidizing status.

Harmful effects of homocystein appear in the result of the production of oxidants and accumulation of disulphides in the blood. The production of oxidants occurs while reduction of homocystein to homocystin and the accumulation of disulphides while the reaction of homocystein with protein thiol groups. The most reactive product is thiolacton along this pathway [15].

Cystathionin-beta synthase deficiency or catalase deficiency by B6 (pyridoxin) shows homocysteinemia and methioninemia, and mental retardation and seizures appear in homocystinuria Type 1. Eye damage also occurs in the result of deficiency in glutathione synthesis as an antioxidant agent, because of low cysteine levels [18].

Homocysteinemia but low methionine levels occurs in type 2, 3, 4 homocystinuria and these patients do not have mental retardation nor seizures [19, 20].

Type 1 homocystinuria is a rare disease and treated with vitamin B6 and cysteine [18]. Other types of homocystinuria seem more frequently, and improve with vitamin B12 and folate or sometimes diet with methionine because of methionine synthetase deficiency [19]. Another treatment choice is betaine= tri-

methylglucoside (Cystadone 4g/180 ml) also a methylating agent [20, 21, 22].

### Enzyme Defects

Until today, some enzyme defects are defined on homocystinuria patients.

- 1. Methylene tetrahydrofolate reductase deficiency (type 2):** Methionine level is decreased in this autosomal recessive enzyme defect. And low choline levels are defined in brain tissue. Methionine level is increased by giving betaine [remethylating agent] in diet or as a drug. Other enzyme defects lead to low methionine levels are methionine synthase and methionine synthase reductase deficiency [19, 23, 24, 25, 26].
- 2. Cystathionin beta synthase deficiency (type 1):** Homocysteinemia and methioninemia are defined in this autosomal recessive disorder with the symptoms malar rash, thin hair and cutis marmorata [21, 24, 25, 26, 27, 28].
- 3. Transcobalamin deficiency:** In this autosomal recessive disorder, vitamin B12 cannot transport in the cell, with the symptoms microcephaly, megaloblastic anemia, mental retardation, seizures, cerebral atrophy, muscular dystonia (cbIE type), and other type (cbIC) is also autosomal recessive disorder with homocystinuria and methylmalonic aciduria [1, 6, 29, 30, 31, 32].
- 4. Adenosyl methionine transferase deficiency:** S-adenosylmethionine (AdoMet) lies at an intersection of nucleotide and amino acid metabolism and performs a multitude of metabolic functions. The bioenergetic systems convert environmental calories into ATP, acetyl-Coenzyme A (acetyl-CoA), S-adenosyl-methionine (SAM) and reduced NAD(+). Folate-deficient, iron-rich diet, transgenic mice lacking in apolipoprotein E (ApoE<sup>-/-</sup> mice) demonstrate impaired activity of glutathione S-transferase (GST), resulting in increased oxidative species within brain tissue despite abnormally high levels of glutathione. These mice also exhibit reduced levels of S-adenosyl methionine ([SAM) and increased levels of its hydrolysis product S-adenosyl homocysteine, which inhibits SAM usage. The mechanism by which Vitamin B12 prevents

demyelination of nerve tissue is still not known. The evidence indicates that the critical site of B12 function in nerve tissue is in the enzyme, methionine synthase, in a system which requires S-adenosylmethionine. In recent years it has been recognized that S-adenosylmethionine gives rise to the deoxyadenosyl radical which catalyzes many reactions including the rearrangement of lysine to beta-lysine [33].

### Other diseases with homocystinuria

Homocystinuria was found in several disease and syndrome as Behçet's disease, diabetes, metabolic syndrome, cardiovascular diseases, thrombosis [34, 35, 36, 37, 38] mental illness, nephropathia but still in discussion. Although, marfanoid persons have exactly related homocystinuria and the treatment of homocystinuria is also changed phenotype [2, 39]. Because of these reasons, homocystinuria test is involved in newborn screening panel, recently [40, 41, 42, 43].

### Excel Diet for Homocystinuria

Methionine restricted diet is need to avoid these foods, contain methionine: meat, fish, yogurt, beans, eggs, onion, garlic, lentils, sesame seeds, wheatgerm, soy protein concentrate, oat, peanuts, corn yellow, rice brown. Methionine restricted diet have supported longer life span in experimental animal studies.

Patients can consume these foods contain cysteine: poultry, wheat, broccoli, red pepper [44].

Onion, garlic, eggs are also contain both of cysteine and methionine.

Cystathionin is composed of methionine and serin by cystathionin beta synthase [27] and transform to cysteine by cystathionin gamma lysase. Cysteine is nonessential aminoacid but may be essential in newborn, olders, malabsorption and metabolic syndromes [15].

The respectable antioxidant glutathion is composed of cysteine, glycine and glutamic

acid and prevents lens dislocation in this syndrome [5, 15].

### References

1. Cook S, Hess OM. Homocysteine and B vitamins. *Handb Exp Pharmacol* 2005; (170): 325-382. PMID: 16596805.
2. Aguirre Errasti C, Egurbide Arberas MV, Martinez Berriotxo A. Present role of homocysteine in clinical medicine. *Med Clin (Barc)* 2009; 133: 472-478. PMID: 19359001
3. Wang XS, Zhang JG, Qiu GX, et al. Clinical diagnosis and surgical treatment of congenital contractual arachnodactyly: analysis of 6 cases. *Zhonghua Yi Xue Za Zhi* 2008; 88: 615-618. PMID: 18646717
4. Maillot F, Kraus JP, Lee PJ. Environmental influences on familial discordance of phenotype in people with homocystinuria: a case report. *J Med Case Reports*. 2008; 2: 113. PMID: 18423051
5. Kanigowska K, Gratek M. Lens dislocation in children. *Klin Oczna* 2006; 108: 90-92. PMID: 16883950
6. Gerth C, Morel CF, Feigenbaum A, Levin AV. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type. *J AAPOS* 2008; 12: 591-596. PMID: 18848477
7. Varlibas F, Cobanoglu O, Ergin B, Tireli H. Different phenotypy in three siblings with homocystinuria. *Neurologist* 2009; 15: 144-146. PMID: 19430269
8. Hubmacher D, Cirulis JT, Miao M, et al. Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. *J Biol Chem* 2009 Nov 4 [Epub ahead of print] PMID: 19889633
9. Heil SG, Hogeveen M, Kluijtmans LA et al. Marfanoid features in a child with combined methylmalonic aciduria and homocystinuria (CblC type). *J Inheret Metab Dis* 2007; 30: 811. PMID: 17768669
10. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. *Antioxid Redox Signal* 2006; 8: 338-346. PMID: 16677079
11. Hubmacher D, Tiedemann K, Bartels R, et al. Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential pathogenetic mechanism in homocystinuria. *J Biol Chem* 2005; 280: 34946-34955. PMID: 16096271.
12. Elsaid MF, Bener A, Lindner M, et al. Are heterozygotes for classical homocystinuria at risk of vitamin B12 and folic acid deficiency? *Mol Genet Metab* 2007; 92: 100-103. PMID: 17686644
13. Gherasim C, Rosenblatt DS, Banerjee R. Polymorphic background of methionine synthase reductase modulates the phenotype of a disease-causing mutation. *Hum Mutat* 2007; 28: 1028-1033. PMID: 17554763.
14. Sinclair AJ, Barling L, Nightingale S. Recurrent dystonia in homocystinuria: a metabolic pathogenesis. *Mov Disord* 2006; 21: 1780-1782. PMID: 16856143
15. Elshorbagy AK, Nurk E, Gjesdal CG, et al. Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino

- acid and lipid metabolism? *Am J Clin Nutr* 2008; 88: 738-746. PMID: 18779291
16. Hashimoto T, Shinohara Y, Hasegawa H. Homocysteine metabolism. *Yakugaku Zasshi*. 2007; 127: 1579-1592. PMID: 17917419
  17. Alberto JM, Hamelet J, Noll C, et al. Mice deficient in cystathionine beta synthase display altered homocysteine remethylation pathway. *Mol Genet Metab* 2007; 91: 396-398. PMID: 17562377
  18. Clayton PT. B6-responsive disorders: a model of vitamin dependency. *J Inherit Metab Dis* 2006; 29: 317-326. PMID: 16763894
  19. McCully KS. Homocysteine, vitamins, and vascular disease preven on. *Am J Clin Nutr* 2007; 86: 1563S-1568S. PMID: 17991676
  20. Ucar SK, Koroğlu OA, Berk O, et al. Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency. *Eur J Pediatr* 2009 May 12 [Epub ahead of print]. PMID: 19434424
  21. Yokoi K, Ito T, Ohkubo Y, et al. Long follow up of betaine therapy in two Japanese siblings with cystathionine beta-synthase deficiency. *Pediatr Int* 2008; 50: 694-695. PMID: 19261122.
  22. Lawson-Yuen A, Levy HL The use of betaine in the treatment of elevated homocysteine. *Mol Genet Metab* 2006; 88: 201-207. PMID: 16545978
  23. Birnbaum T, Blom HJ, Prokisch H, et al. Methylene-tetrahydrofolate reductase deficiency (homocystinuria type II) as a rare cause of rapidly progressive tetraspasticity and psychosis in a previously healthy adult. *J Neurol* 2008; 255: 1845-1846. PMID: 18854913
  24. Jakubowski H, Boers GH, Strauss KA. Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylation protein levels in humans. *FASEB J* 2008; 22: 4071-4076. PMID: 18708589
  25. Bishop L, Kanoff R, Charnas L, et al. Severe methylenetetrahydrofolate reductase (MTHFR) deficiency: a case report of nonclassical homocystinuria. *J Child Neurol* 2008; 23: 823-828. PMID: 18658082
  26. Cohen Aubart F, Sedel F, Papo T. Cystathionine beta-synthase and MTHFR deficiencies in adults] *Rev Neurol (Paris)* 2007; 163: 904-910. PMID: 18033026
  27. Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. *Mol Genet Metab* 2009 Sep 27 [Epub ahead of print] PMID: 19819175
  28. Rao TN, Radhakrishna K, Mohana Rao TS, Guruprasad P, Ahmed K. Homocystinuria due to cystathionine beta synthase deficiency. *Indian J Dermatol Venereol Leprol* 2008; 74: 375-378. PMID: 18797062
  29. Richard E, Jorge-Finnigan A, Garcia-Villoria J, et al. Genetic and cellular studies of oxidative stress in methylmalonic aciduria (MMA) cobalamin deficiency type C (cblC) with homocystinuria (MMACHC). *Hum Mutat* 2009; 30: 1558-1566. PMID: 19760748
  30. Froese DS, Zhang J, Healy S, Gravel RA. Mechanism of vitamin B12-responsiveness in cblC methylmalonic aciduria with homocystinuria. *Mol Genet Metab* 2009; 98: 338-343. PMID: 19700356
  31. Coelho D, Suormala T, Stucki M, et al. Gene identification for the cblD defect of vitamin B12 metabolism. *N Eng J Med* 2008;358: 1454-1464. PMID: 18385497
  32. Ueland PM, Schneede J. Measurement of methylmalonic acid, homocysteine and methionine in cobalamin and folate deficiencies and homocystinuria. *Tidsskr Nor Laegeforen* 2008; 128: 690-693. PMID: 18337849
  33. Couce ML, Bóveda MD, Castiñeiras DE, et al. Hypermethioninaemia due to methionine adenosyltransferase I/III (MAT I/III) deficiency: Diagnosis in an expanded neonatal screening programme. *J Inherit Metab Dis* 2008 May 20. PMID: 18560573
  34. Tessonnier L, Guedj E, Cano A, et al. Multiple distal pulmonary arterial thromboses revealed by lung scintigraphy in a patient with homocystinuria and normal multidetector CT pulmonary angiography. *Clin Nucl Med* 2009; 34: 42-43. PMID: 19092386
  35. Lonn E. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction? *Curr Opin Hematol* 2007; 14: 481-487. PMID: 17934354
  36. Bendini MG, Lanza GA, Mazza A, et al. Risk factors for cardiovascular diseases: what is the role for homocysteine? *G Ital Cardiol (Rome)* 2007; 8: 148-160. PMID: 17461357
  37. Quéré I, Gris JC, Dauzat M. Homocysteine and venous thrombosis. *Semin Vasc Med* 2005; 5: 183-189. PMID: 16047270.
  38. Moat SJ, McDowell IF. Homocysteine and endothelial function in human studies. *Semin Vasc Med* 2005; 5: 172-182. PMID: 16047269
  39. Azzabi S, Barhoumi A, Omar S, et al. Late revelation of homocystinuria: clinical, biological and progressive aspects. *Pathol Biol (Paris)* 2009; 57: 451-455. PMID: 19046831
  40. Gan-Schreier H, Kebbewar M, Fang-Hoffmann J, et al. Newborn population screening for classic homocystinuria by determination of total homocysteine from Guthrie cards. *J Pediatr* 2009 Nov 13. PMID: 19914636
  41. Weisfeld-Adams JD, Morrissey MA, Kirmse BM, et al. Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. *Mol Genet Metab* 2009 Sep 27. [Epub ahead of print] PMID: 19836982
  42. Alfonso I, Charria G. Updating neonatal neurometabolic screening. *Medicina (B Aires)* 2009; 69: 36-40. PMID: 19359001
  43. Kaye CI, Accurso F, La Franchi S, et al. Newborn screening fact sheets. *Pediatrics*. 2006; 118: e934-e936. PMID: 16950473
  44. Lee PJ, Briddon A. A rationale for cystine supplementation in severe homocystinuria. *J Inherit Metab Dis* 2007; 30: 35-38. PMID: 17186416